Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (3470)	6/9/2022 7:48:13 AM
From: BioBait	Respond to of 3557

< Thoughts on REGN buying out SNY for PD1? I see it as a vote of confidence and writing was on all since they never opted in for any of the bispecifics that REGN praises> I like the buy out. It will give REGN the opportunity to grow internationally and benefit if they are successful growing Libtayo. REGN hasn’t shown the ability to compete against keytruda so the risk is high. REGN has the cash so why not try. Short term it will impact earnings; but then Regn can do more buybacks. Should work out by 2025. Hoping to pick up some more shares <$600.